title: Relationship between hepatitis C virus recurrence and de novo diabetes after liver transplantation: the Hungarian experience.
abstract: De novo diabetes mellitus is a common complication after liver transplantation. It is strongly associated with hepatitis C virus (HCV) infection. We analyzed the relationship between HCV recurrence and de novo diabetes among the Hungarian liver transplant population. This retrospective study included cases from 1995 to 2009 on 310 whole liver transplantations. De novo diabetes was defined if the patient had a fasting plasma glucose ≥126 mg/dL permanently after the third month post liver transplantation, and/or required sustained antidiabetic therapy. De novo diabetes occured in 63 patients (20%). The cumulative patient survival rates at 1, 3, 5, and 8 years were 95%, 91%, 88%, and 88% in the control group, and 87%, 79%, 79%, and 64% in the de novo group, respectively (P=.011). The majority of the patients in the de novo group were HCV positive (66% vs 23%). Early virus recurrence within 5 months was associated with the development of diabetes (80% vs 20% non-diabetic controls; P=.017). The fibrosis (2.05 ± 1.5 vs 1 ± 1; P=.039) and Knodell scores (3.25 ± 2 vs 1.69 ± 1.2; P=.019) were higher among the de novo group after antiviral therapy. Rapid recurrence, more severe viremia, and fibrosis showed significant roles in the developement of de novo diabetes after liver transplantation.
authors.affiliation: Departure of Transplantation and Surgery, Semmelweis University Budapest, Hungary. fanni.gelley@gmail.com
authors.forename: F
authors.initials: F
authors.lastname: Gelley
authors.forename: G
authors.initials: G
authors.lastname: Zadori
authors.forename: G
authors.initials: G
authors.lastname: Firneisz
authors.forename: L
authors.initials: L
authors.lastname: Wagner
authors.forename: I
authors.initials: I
authors.lastname: Fehervári
authors.forename: Z
authors.initials: Z
authors.lastname: Gerlei
authors.forename: J
authors.initials: J
authors.lastname: Fazakas
authors.forename: S
authors.initials: S
authors.lastname: Papai
authors.forename: G
authors.initials: G
authors.lastname: Lengyel
authors.forename: E
authors.initials: E
authors.lastname: Sarvary
authors.forename: B
authors.initials: B
authors.lastname: Nemes
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D006814:Hungary; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000401:mortality / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014766:Viremia
chemical_list: D000998:Antiviral Agents; D007004:Hypoglycemic Agents